Synopsis
Synopsis
0
JDMF
0
VMF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4-nitro-2-phenoxymethanesulfonanilide
2. Antifloxil
3. Aulin
4. Eskaflam
5. Guaxan
6. Lizepat
7. Mesulid
8. Nexen
9. Nimesil
10. R 805
11. R-805
12. Redaflam
1. 51803-78-2
2. N-(4-nitro-2-phenoxyphenyl)methanesulfonamide
3. Mesulid
4. Aulin
5. Flogovital
6. Sulidene
7. Nimed
8. 4-nitro-2-phenoxymethanesulfonanilide
9. R-805
10. Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-
11. R 805
12. Nisulid
13. 4'-nitro-2'-phenoxymethanesulfonanilide
14. 4-nitro-2-phenoxy-methanesulfonanilide
15. Nsc-758412
16. Chembl56367
17. Mls000069680
18. V4tkw1454m
19. Methanesulfonanilide, 4'-nitro-2'-phenoxy-
20. Chebi:44445
21. Ncgc00015725-02
22. R805
23. Smr000058484
24. Cas-51803-78-2
25. Dsstox_cid_17250
26. Dsstox_rid_79316
27. Dsstox_gsid_37250
28. Antifloxil
29. Nimesulida
30. Nimesulidum
31. Guaxan
32. Nimesulidum [inn-latin]
33. Nimesulida [inn-spanish]
34. Nim
35. Nimesulide [inn:ban]
36. Sr-01000000218
37. Einecs 257-431-4
38. 4'-nitro-2'-phenoxymethansulfonanilid
39. Brn 2421175
40. Unii-v4tkw1454m
41. Aldoron
42. Nimedex
43. Orthobid
44. Ccris 8225
45. Nise Gel
46. Nimesulide,(s)
47. Prestwick_618
48. Mfcd00079470
49. Spectrum_001577
50. Nimesulide [mi]
51. Nimesulide (jan/inn)
52. Nimesulide [inn]
53. Nimesulide [jan]
54. Opera_id_1247
55. Prestwick0_000194
56. Prestwick1_000194
57. Prestwick2_000194
58. Prestwick3_000194
59. Spectrum2_001541
60. Spectrum3_001576
61. Spectrum4_000178
62. Spectrum5_000964
63. Lopac-n-1016
64. N-(4-nitro-2-phenoxy-phenyl)methanesulfonamide
65. Nimesulide [mart.]
66. Nimesulide [who-dd]
67. Lopac0_000855
68. Schembl24882
69. Bspbio_000147
70. Bspbio_001103
71. Bspbio_003112
72. Kbiogr_000443
73. Kbiogr_000695
74. Kbioss_000443
75. Kbioss_002057
76. Mls001148268
77. Divk1c_000693
78. Spectrum1503231
79. Spbio_001382
80. Spbio_002068
81. N-(4-nitro-2-phenoxyphenyl)
82. Bpbio1_000163
83. Gtpl7401
84. Nim-03
85. Dtxsid3037250
86. Nimesulide [ep Impurity]
87. Bcbcmap01_000034
88. Hms502c15
89. Kbio1_000693
90. Kbio2_000443
91. Kbio2_002057
92. Kbio2_003011
93. Kbio2_004625
94. Kbio2_005579
95. Kbio2_007193
96. Kbio3_000825
97. Kbio3_000826
98. Kbio3_002612
99. Nimesulide [ep Monograph]
100. Nimesulide For Peak Identification
101. Ninds_000693
102. Bio2_000382
103. Bio2_000862
104. Hms1362g05
105. Hms1568h09
106. Hms1792g05
107. Hms1922k17
108. Hms1990g05
109. Hms2089b14
110. Hms2095h09
111. Hms2234k19
112. Hms3262l11
113. Hms3269g17
114. Hms3371j19
115. Hms3403g05
116. Hms3414p09
117. Hms3649a04
118. Hms3655d13
119. Hms3678p07
120. Hms3712h09
121. Hms3884c22
122. Pharmakon1600-01503231
123. Bcp10076
124. Hy-b0363
125. Zinc4617749
126. Tox21_110207
127. Tox21_301850
128. Tox21_500855
129. Bdbm50056999
130. Ccg-39319
131. Ei-287
132. Nsc758412
133. S2040
134. Stl018679
135. Akos015897356
136. Tox21_110207_1
137. Ac-4524
138. Db04743
139. Ks-1277
140. Lp00855
141. Nsc 758412
142. Sdccgsbi-0050831.p004
143. Idi1_000693
144. Idi1_002137
145. Ncgc00015725-01
146. Ncgc00015725-03
147. Ncgc00015725-04
148. Ncgc00015725-05
149. Ncgc00015725-06
150. Ncgc00015725-07
151. Ncgc00015725-08
152. Ncgc00015725-09
153. Ncgc00015725-10
154. Ncgc00015725-11
155. Ncgc00015725-12
156. Ncgc00015725-13
157. Ncgc00015725-15
158. Ncgc00015725-16
159. Ncgc00015725-29
160. Ncgc00021842-03
161. Ncgc00021842-04
162. Ncgc00021842-05
163. Ncgc00021842-06
164. Ncgc00021842-07
165. Ncgc00021842-08
166. Ncgc00255661-01
167. Ncgc00261540-01
168. Bn166246
169. Nimesulide 100 Microg/ml In Acetonitrile
170. Sbi-0050831.p003
171. Db-052029
172. Ab00052332
173. Eu-0100855
174. Ft-0630650
175. N0984
176. Sw196785-3
177. D01049
178. D70376
179. N 1016
180. Q20994
181. Ab00052332-16
182. Ab00052332_17
183. Ab00052332_18
184. N-[4-nitro-2-(phenoxy)phenyl]methanesulfonamide
185. 803n782
186. A828786
187. Sr-01000000218-2
188. Sr-01000000218-6
189. Sr-01000000218-7
190. W-105866
191. Brd-k76775527-001-06-2
192. Brd-k76775527-001-18-7
193. Sr-01000000218-11
194. Nimesulide, European Pharmacopoeia (ep) Reference Standard
195. Nimesulide, Pharmaceutical Secondary Standard; Certified Reference Material
196. Nimesulide For Peak Identification, European Pharmacopoeia (ep) Reference Standard
197. 1364966-82-4
| Molecular Weight | 308.31 g/mol |
|---|---|
| Molecular Formula | C13H12N2O5S |
| XLogP3 | 2.6 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 4 |
| Exact Mass | 308.04669266 g/mol |
| Monoisotopic Mass | 308.04669266 g/mol |
| Topological Polar Surface Area | 110 Ų |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 450 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old.
Food, gender and advanced age have negligible effects on nimesulide pharmacokinetics.
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)
Cyclooxygenase Inhibitors
Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes. (See all compounds classified as Cyclooxygenase Inhibitors.)
M - Musculo-skeletal system
M01 - Antiinflammatory and antirheumatic products
M01A - Antiinflammatory and antirheumatic products, non-steroids
M01AX - Other antiinflammatory and antirheumatic agents, non-steroids
M01AX17 - Nimesulide
M - Musculo-skeletal system
M02 - Topical products for joint and muscular pain
M02A - Topical products for joint and muscular pain
M02AA - Antiinflammatory preparations, non-steroids for topical use
M02AA26 - Nimesulide
Absorption
Rapidly absorbed following oral administration.
Route of Elimination
Renal (50%), fecal (29%)
Hepatic. Extensive biotransformation, mainly to 4-hydroxynimesulide (which also appears to be biologically active).
1.84.7 hours
The therapeutic effects of Nimesulide are the result of its complete mode of action which targets a number of key mediators of the inflammatory process such as: COX-2 mediated prostaglandins, free radicals, proteolytic enzymes and histamine.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
Towa Pharma is dedicated to researching, developing, producing, and promoting generic drugs.
Regulatory Info :
Registration Country : Italy
Brand Name : NIMESULIDES THINKS
Dosage Form : Granules For Oral Suspension
Dosage Strength : 100 mg
Packaging : 30 UNITS 100 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Towa Pharma is dedicated to researching, developing, producing, and promoting generic drugs.
Regulatory Info :
Registration Country : Italy
Brand Name : NIMESULIDES THINKS
Dosage Form : Tablet
Dosage Strength : 100mg
Packaging : 30 UNITS 100 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : EFRIDOL
Dosage Form : Granules For Oral Suspension
Dosage Strength : 100mg
Packaging : 30 UNITS 100 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : NIMESULIDE DOC GENERIC
Dosage Form : Tablet
Dosage Strength : 100mg
Packaging : 30 UNITS 100 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : Aulin Mild
Dosage Form :
Dosage Strength : 30 Bust Grat 50 Mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info : Generic
Registration Country : Turkey
Brand Name : Nimesdin Plus
Dosage Form : Gel
Dosage Strength : 1%; 5%
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Turkey
Regulatory Info :
Registration Country : Italy
Brand Name : NIMESULENE
Dosage Form : Granules For Oral Suspension
Dosage Strength : 100 mg
Packaging : 30 UNITS 100 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : Nesulide
Dosage Form : Nimesulide 100Mg 30 Joined' Oral Use
Dosage Strength : 30 bust grat 100 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : NIMESULIDE RATIOPHARM
Dosage Form : Granules For Oral Suspension
Dosage Strength : 100 mg
Packaging : 30 UNITS 100 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : Efridol
Dosage Form : Nimesulide 100Mg 30 Joined' Oral Use
Dosage Strength : 30 bust grat 100 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
97
PharmaCompass offers a list of Nimesulide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Nimesulide manufacturer or Nimesulide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Nimesulide manufacturer or Nimesulide supplier.
PharmaCompass also assists you with knowing the Nimesulide API Price utilized in the formulation of products. Nimesulide API Price is not always fixed or binding as the Nimesulide Price is obtained through a variety of data sources. The Nimesulide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Nimesulidum manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nimesulidum, including repackagers and relabelers. The FDA regulates Nimesulidum manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nimesulidum API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nimesulidum manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Nimesulidum supplier is an individual or a company that provides Nimesulidum active pharmaceutical ingredient (API) or Nimesulidum finished formulations upon request. The Nimesulidum suppliers may include Nimesulidum API manufacturers, exporters, distributors and traders.
click here to find a list of Nimesulidum suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Nimesulidum DMF (Drug Master File) is a document detailing the whole manufacturing process of Nimesulidum active pharmaceutical ingredient (API) in detail. Different forms of Nimesulidum DMFs exist exist since differing nations have different regulations, such as Nimesulidum USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Nimesulidum DMF submitted to regulatory agencies in the US is known as a USDMF. Nimesulidum USDMF includes data on Nimesulidum's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Nimesulidum USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Nimesulidum suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Nimesulidum Drug Master File in Korea (Nimesulidum KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Nimesulidum. The MFDS reviews the Nimesulidum KDMF as part of the drug registration process and uses the information provided in the Nimesulidum KDMF to evaluate the safety and efficacy of the drug.
After submitting a Nimesulidum KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Nimesulidum API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Nimesulidum suppliers with KDMF on PharmaCompass.
A Nimesulidum CEP of the European Pharmacopoeia monograph is often referred to as a Nimesulidum Certificate of Suitability (COS). The purpose of a Nimesulidum CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Nimesulidum EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Nimesulidum to their clients by showing that a Nimesulidum CEP has been issued for it. The manufacturer submits a Nimesulidum CEP (COS) as part of the market authorization procedure, and it takes on the role of a Nimesulidum CEP holder for the record. Additionally, the data presented in the Nimesulidum CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Nimesulidum DMF.
A Nimesulidum CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Nimesulidum CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Nimesulidum suppliers with CEP (COS) on PharmaCompass.
A Nimesulidum written confirmation (Nimesulidum WC) is an official document issued by a regulatory agency to a Nimesulidum manufacturer, verifying that the manufacturing facility of a Nimesulidum active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Nimesulidum APIs or Nimesulidum finished pharmaceutical products to another nation, regulatory agencies frequently require a Nimesulidum WC (written confirmation) as part of the regulatory process.
click here to find a list of Nimesulidum suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Nimesulidum as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Nimesulidum API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Nimesulidum as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Nimesulidum and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Nimesulidum NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Nimesulidum suppliers with NDC on PharmaCompass.
Nimesulidum Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nimesulidum GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nimesulidum GMP manufacturer or Nimesulidum GMP API supplier for your needs.
A Nimesulidum CoA (Certificate of Analysis) is a formal document that attests to Nimesulidum's compliance with Nimesulidum specifications and serves as a tool for batch-level quality control.
Nimesulidum CoA mostly includes findings from lab analyses of a specific batch. For each Nimesulidum CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nimesulidum may be tested according to a variety of international standards, such as European Pharmacopoeia (Nimesulidum EP), Nimesulidum JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nimesulidum USP).
